{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:12:21Z","timestamp":1792501941845,"version":"4.5.0"},"reference-count":0,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2013,1,21]],"date-time":"2013-01-21T00:00:00Z","timestamp":1358726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2013,1,21]]},"abstract":"<jats:p>\n                    Dimebon belongs to a fast-growing group of \u201cold\u201d drugs that were suggested to be effective for therapy of pathological conditions different from their original targets. Following initial reports of successful Phase II clinical trials for mild-to-moderate Alzheimer's and Huntington's diseases, effects of Dimebon on various neurodegenerative conditions were investigated both in follow-up clinical trials and in various model systems. Although results of Phase III clinical trials carried out so far were disappointing, there is growing body of evidence that this drug can affect neuronal physiology in a way that would be beneficial at particular stages of development of certain types of neurodegeneration. To reveal what molecular and cellular pathological processes might be affected by Dimebon, we tested the ability of this drug to ameliorate pathology in model systems recapitulating particular pathogenic mechanisms involved in the development and progression of neurodegenerative diseases. Here we assessed the ability of Dimebon to modify several prominent features of tauopathies using transgenic tau\n                    <jats:sup>P301S<\/jats:sup>\n                    mice as a model. Chronic treatment with Dimebon was found to partially protect against the progressive decline in motor function and accumulation of tau-positive dystrophic neurons characteristic of tau\n                    <jats:sup>P301S<\/jats:sup>\n                    mice. Similar results were obtained with two further \u03b3-carbolines structurally similar to Dimebon. Our data suggest that Dimebon and Dimebon-like compounds might be considered as drugs possessing disease-modifying activity for diseases with prominent tau pathology.\n                  <\/jats:p>","DOI":"10.3233\/jad-2012-121732","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T05:55:13Z","timestamp":1528091713000},"page":"1041-1049","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":45,"title":["Chronic Administration of Dimebon Ameliorates Pathology in Tau\n                    <sup>P301S<\/sup>\n                    Transgenic Mice"],"prefix":"10.1177","volume":"33","author":[{"given":"Owen M.","family":"Peters","sequence":"first","affiliation":[{"name":"School of Biosciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Connor-Robson","sequence":"additional","affiliation":[{"name":"School of Biosciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir B.","family":"Sokolov","sequence":"additional","affiliation":[{"name":"Institute of Physiologically Active Compounds of RAS, Chernogolovka, Moscow Region, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey Yu.","family":"Aksinenko","sequence":"additional","affiliation":[{"name":"Institute of Physiologically Active Compounds of RAS, Chernogolovka, Moscow Region, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail S.","family":"Kukharsky","sequence":"additional","affiliation":[{"name":"Institute of Physiologically Active Compounds of RAS, Chernogolovka, Moscow Region, Russian Federation"},{"name":"Institute of General Pathology and Pathophysiology of Russian Academy of Medical Science, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey O.","family":"Bachurin","sequence":"additional","affiliation":[{"name":"Institute of Physiologically Active Compounds of RAS, Chernogolovka, Moscow Region, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Ninkina","sequence":"additional","affiliation":[{"name":"School of Biosciences, Cardiff University, Cardiff, UK"},{"name":"Institute of Physiologically Active Compounds of RAS, Chernogolovka, Moscow Region, Russian Federation"},{"name":"Institute of General Pathology and Pathophysiology of Russian Academy of Medical Science, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir L.","family":"Buchman","sequence":"additional","affiliation":[{"name":"School of Biosciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,1,21]]},"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-2012-121732","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-2012-121732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:02:00Z","timestamp":1777370520000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-2012-121732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,21]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,1,21]]}},"alternative-id":["10.3233\/JAD-2012-121732"],"URL":"https:\/\/doi.org\/10.3233\/jad-2012-121732","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1007\/s12035-017-0745-6","asserted-by":"object"}]},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,21]]}}}